Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 21, 2021 17:27 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON) (“TRACON” or the “Company”), a clinical stage biopharmaceutical company focused on the development and...
July 20, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
June 30, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
June 29, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma

Application Included Clinical Trial Data from Soft Tissue Sarcoma Patients Treated with Envafolimab in Phase 1 Trials SAN DIEGO, June 29, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:...
June 04, 2021 09:01 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
June 01, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

SAN DIEGO, June 01, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
May 25, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
May 20, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Poster Presentations at the 2021 ASCO Virtual Annual Meeting

SAN DIEGO, May 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...
May 05, 2021 16:03 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer...
May 03, 2021 08:05 ET | Source: TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals Announces Appointment of Dongliang Zhuang, Ph.D. as Vice President of Statistics and Biometrics

SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...